SCHEMBL21643035

SCHEMBL21643035

N#Cc1cn2cc(C[C@H](N)C(=O)O)cnc2n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.39
SLC7A5 Q01650 4/20 0.38
PTGS1 P23219 3/20 0.38
ALPI P09923 1/20 0.38
PKM P14618 1/20 0.38
XIAP P98170 1/20 0.38
TPH1 P17752 1/20 0.38
TYR P14679 5/20 0.37
SLC1A3 P43003 1/20 0.35
ITGB3 P05106 1/20 0.34
ITGA2B P08514 1/20 0.34
ALOX15 P16050 3/20 0.34
HIF1A Q16665 3/20 0.34
KDM4E B2RXH2 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
GRIA2 P42262 2/20 0.34
USP2 O75604 1/20 0.34
EGFR P00533 1/20 0.34
LCK P06239 1/20 0.34
FYN P06241 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21643037 1.00 HSD17B10 (0.39) HSD17B10SLC7A5PTGS1ALPIPKM
SCHEMBL21643023 0.79 TYR (0.47) HSD17B10SLC7A5PTGS1ALPIPKM
SCHEMBL21643024 0.79 TYR (0.47) HSD17B10SLC7A5PTGS1ALPIPKM
SCHEMBL21643077 0.78 CYP1A2 (0.35) HSD17B10SLC7A5PTGS1ALPIPKM
SCHEMBL21643076 0.78 CYP1A2 (0.35) HSD17B10SLC7A5PTGS1ALPIPKM
SCHEMBL31754344 0.75 HSD17B10 (0.49) HSD17B10SLC7A5PTGS1ALPIPKM
SCHEMBL25657792 0.74 HSD17B10 (0.53) HSD17B10SLC7A5PTGS1ALPIPKM
SCHEMBL21689086 0.69 KDM4E (0.30) KDM4E
SCHEMBL7405224 0.68 HSD17B10 (0.51) HSD17B10SLC7A5PTGS1ALPIPKM
SCHEMBL7405225 0.68 HSD17B10 (0.51) HSD17B10SLC7A5PTGS1ALPIPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11319347-B2 Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound FUJIFILM CORPORATION (JP) 2022-05-03 US disclosed
US-20200040039-A1 PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND FUJIFILM CORPORATION (JP) 2020-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200040039-A1 PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND VIP, NPPA, NGLY1 HSD17B10 3726/4885SLC7A5 113/4885PTGS1 2097/4885
US-11319347-B2 Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound VIP, NPPA, NGLY1 HSD17B10 3726/4885SLC7A5 113/4885PTGS1 2097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.